The Skin Cancer Education and Research Foundation – Home › Forums › Immunotherapy › Expectations for therapy › Adjuvant pembrolizumab › Reply To: Adjuvant pembrolizumab
January 21, 2018 at 3:47 pm #4612
Expert NurseKathleen Madden
Well stated, Virginia!
An additional point- a more general one for PD-1 inhibitors, since so many changes are occurring so rapidly, checking the PI information on the manufacturers web site will provide the most up to date prescrbing and administration guidelines, and more changes are slated ahead!